The Direct Coombs Test, also called the Direct Antiglobulin Test (DAT), is a blood test that checks whether antibodies (or certain immune proteins called complement) are stuck to the surface of your red blood cells. Normally, red blood cells circulate freely. In some conditions—often related to autoimmunity or a reaction after a transfusion—your immune system may mistakenly “tag” red blood cells, which can cause them to be broken down too early (a process called hemolysis).

In simple terms, the test helps answer: “Is the immune system attacking the red blood cells?” In the lab, your red blood cells are mixed with a reagent (Coombs/antiglobulin reagent). If antibodies or complement are attached to your red blood cells, the cells may clump together (agglutinate), indicating a positive result.

What results generally mean:

Negative DAT (Direct Coombs): No significant antibodies/complement were detected on the red blood cell membrane. This makes immune-mediated hemolysis less likely, though it does not completely rule it out in every case.

Positive DAT (Direct Coombs): Antibodies and/or complement are present on red blood cells. This supports conditions such as autoimmune hemolytic anemia, a transfusion reaction, or hemolytic disease of the newborn (often related to rhesus mismatch or other blood group incompatibilities). Your clinician will interpret the result alongside other tests (like hemoglobin, bilirubin, LDH, haptoglobin, and a reticulocyte count) and your symptoms.

A Direct Coombs Test is usually ordered when a clinician suspects that red blood cells are being destroyed faster than they should be due to an immune cause. It is commonly part of an evaluation for hemolytic anemia (anemia from red blood cell breakdown) or when there is concern about a blood incompatibility reaction.

Your doctor may order this test if you have signs or lab findings suggestive of hemolysis, such as:

Symptoms: fatigue, weakness, shortness of breath, rapid heartbeat, pale skin, dizziness, or dark/tea-colored urine.

Possible hemolysis-related findings: jaundice (yellowing of skin/eyes), an enlarged spleen, or unexplained anemia.

It may also be ordered in these situations:

Suspected autoimmune hemolytic anemia: especially if you have known autoimmune disease, recent infection, or are taking medications that can rarely trigger immune destruction of red blood cells.

After a blood transfusion: if there are symptoms of a transfusion reaction (fever, chills, back pain, dark urine, unexpectedly falling hemoglobin), the Direct Coombs Test helps determine whether the immune system is attacking transfused or your own red blood cells.

Pregnancy and newborn evaluation: if there is concern for hemolytic disease of the fetus and newborn (HDFN) due to blood type incompatibility—classically Rh (rhesus) mismatch (Rh-negative mother, Rh-positive baby) or other incompatibilities. In newborns, it can help explain jaundice or anemia related to maternal antibodies.

Monitoring known immune hemolysis: in some cases, it can support ongoing assessment along with hemolysis markers to understand whether immune coating of red blood cells is present.

• Autoimmune hemolytic anemia (AIHA), including warm and cold antibody types
• Hemolytic disease of the fetus and newborn (HDFN), including Rh (rhesus) mismatch and ABO incompatibility
• Hemolytic transfusion reaction (immune-mediated reaction after blood transfusion)
• Drug-induced immune hemolytic anemia (rare immune reaction to certain medications)
• Hemolysis associated with autoimmune conditions (e.g., systemic lupus erythematosus)

• Identifying immune-related causes of anemia and guiding next steps in diagnosis
• Supporting safe transfusion care by evaluating suspected transfusion reactions
• Pregnancy and newborn health: assessing risk or cause of antibody-mediated newborn jaundice/anemia (including rhesus mismatch)
• Monitoring and managing autoimmune conditions when anemia or hemolysis is suspected
• Clarifying the cause of unexplained jaundice or elevated hemolysis markers as part of a broader workup